Clinical trials are too slow and too costly—here is how to fix them.

Press/Media: Blogs and social media


CLINICAL TRIALS are the gold standard for testing the safety and efficacy of a treatment or drug, and a keystone in modern medicine. But their grinding timelines and skyrocketing price tags are hindering development and, ultimately, costing lives.

Natasha Loder, The Economist’s health editor, asks Sir Martin Landray, the boss of Protas, a clinical-trial organisation, what can be learned from his pioneering RECOVERY covid-19 trial. Euan Ashley, a cardiologist at Stanford University, explains how to use wearable technology to conduct wholly digital clinical trials. Plus, Alejandro Frangi of the University of Leeds says virtual clinical trials that use computers to model medical interventions can save time and money. Alok Jha, The Economist‘s science and technology editor, hosts. Runtime: 39 min

Period24 May 2023

Media contributions


Media contributions

  • TitleClinical trials are too slow and too costly—here is how to fix them
    Degree of recognitionInternational
    Media name/outletThe Economist Podcast
    Media typeWeb
    Country/TerritoryUnited Kingdom
    DescriptionThe Economist podcast on science and technology. In this episode, we examine why this mainstay of modern medicine is ailing, and meet the people trying to make it all better
    PersonsAlejandro F Frangi